MedTrace Logo

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 794

Last updated 2024-12-09

Study results available
· View outcomes & findings →

Summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

MC2-01 cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

DRUG

Cal/BDP combination

calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

DRUG

Cream vehicle

Vehicle Cream

Sponsors & Collaborators

  • MC2 Therapeutics

    lead INDUSTRY

Principal Investigators

  • Linda S. Gold, MD · Henry Ford Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-03
Primary Completion
2018-06-08
Completion
2018-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308799 on ClinicalTrials.gov